Compliance and Ethics Committee Charter

This charter governs the operations of the Compliance and Ethics Committee (the "*Committee*") of the Board of Directors (the "*Board*") of Orthofix Medical Inc. (the "*Company*"). The Committee shall review and assess the adequacy of this charter at least annually and recommend any proposed changes to the Board.

1. Purpose

The Committee shall act on behalf of, and provide assistance to, the Board in overseeing, monitoring, and evaluating:

(a) the activities and the effectiveness of the Company's Global Compliance and Ethics Program;

(b) the activities and the effectiveness of the Company's Global Quality and Regulatory Program;

(c) the Company's compliance with applicable laws, rules, and regulations related to requirements of U.S. federal healthcare programs, requirements of the U.S. Food and Drug Administration ("*FDA*"), requirements of the European Commission of EU, requirements of the U.S. Anti-Kickback Statute, False Claims Act, Physician Self-Referral Law (Stark Law) and Foreign Corrupt Practices Act, and comparable off-label promotion prohibition, anti-kickback, anti-bribery and anti-corruption laws of jurisdictions in which the Company does business (collectively, "*Compliance Laws*");

(d) the Company's compliance with the terms of settlement agreements that the Company or a subsidiary enters into with governmental authorities, as applicable;

(e) compliance with the Company's Code of Conduct, industry codes of conduct, policies, and procedures related to Compliance Laws (collectively, "Compliance Policies"); and

(f) trends and best practices that could affect the Company's business, Global Compliance and Ethics Program, and Global Quality and Regulatory Program.

In so doing, the Committee shall seek to maintain unrestricted and open communication between the members of the Committee and the quality, regulatory and compliance-related personnel of the Company (including, as of the date hereof, the Company's Chief Ethics and Compliance Officer ("*CECO*"), the Senior Vice President, Global Regulatory, Quality and Clinical Affairs, and the Chief Legal Officer), and to endeavor to foster a culture of compliance and ethical behavior throughout the Company. The Committee shall have full power and authority to discharge all of its duties and responsibilities.

2. Membership

The Committee shall be comprised of at least two directors of the Company who are appointed to the Committee by the Board. Members of the Committee shall serve until a successor is duly appointed by the Board or until the member resigns or is removed. The Board may remove any member from the Committee at any time, with or without cause. At least half of the members of the Committee shall have been determined by the Board to be an "independent director" as defined in Nasdaq Listing Rule 5605(a)(2). To the fullest extent permitted by applicable law, any actions

taken by the Committee during any period in which any member (or members) fails for any reason to meet the membership requirements set forth above shall nevertheless be duly authorized actions of the Committee for all corporate purposes.

3. Committee Structure and Operations

The Board shall designate one member of the Committee as its chairperson. The Committee shall meet as often as it determines necessary to carry out its duties and responsibilities. The Committee may establish its own procedures in a manner not inconsistent with this charter, the Company's certificate of incorporation, bylaws and other corporate governance documents, applicable laws, regulations or listing standards (collectively, "*Governance Requirements*").

In discharging its role, the Committee is empowered to investigate any matter brought to its attention with full access to all books, records, facilities, and personnel of the Company. The Committee has the authority to engage independent counsel and other advisers, at the Company's expense, as the Committee may determine necessary to carry out its duties. The Committee may request that any directors, officers or employees of the Company, or other persons whose advice and counsel are sought by the Committee, attend any meeting of the Committee to provide such information as the Committee requests or meet with any member (or members) of, or consultants to, the Committee.

The Committee shall report its significant actions to the Board on a regular basis (to the extent that the full Board has not otherwise been made aware of such actions in the interim, including by guest attendance at the applicable Committee meeting).

4. Duties and Responsibilities

(a) In general, the Committee shall endeavor to promote the Company's operations to be in accordance with Compliance Laws, with an appropriate overall corporate "tone" for compliance and ethical business practices.

(b) In particular, the Committee shall—

1. Oversee, monitor, and evaluate continuing development and implementation of a Global Compliance and Ethics Program, including Compliance Policies designed to prevent and detect violations of Compliance Laws.

2. Oversee, monitor, and evaluate continuing development and implementation of a Global Quality and Regulatory Program, including compliance with FDA Quality Guidelines, European Medical Device Regulations, and quality and regulatory policies and procedures designed to ensure compliance with laws and regulations applicable to the Company products globally, and report to the Board as to the effectiveness of the Company's Global Quality and Regulatory Program.

3. Appoint and oversee the activities of the CECO, who shall report to the Company's Chief Executive Officer, but also shall have "dotted line" responsibility to the chairperson of the Committee, who will have direct access to the CECO. The CECO shall have the responsibility for continually developing and implementing the Company's Global Compliance and Ethics Program and the Committee shall report to the Board as to the effectiveness of the Company's Global Compliance and Ethics Program.

4. Review the activities of the Company's Senior Vice President, Global Regulatory, Quality and Clinical Affairs, who, among other things, has responsibility for

continually developing and implementing the Company's Global Quality and Regulatory Program.

5. Oversee, monitor, and evaluate the Company's implementation as part of its Global Compliance and Ethics Program of:

   i. effective training and education in compliance;

   ii. effective lines of communication regarding compliance matters;

   iii. appropriately designed internal monitoring and auditing;

   iv. regular enforcement of compliance standards; and

   v. prompt responses to detected noncompliance, and undertaking of appropriate corrective action.

6. Oversee, monitor, and evaluate the Company's compliance with and implementation of the terms of any settlement agreements entered into with governmental authorities or warning letters and other directives issued by government agencies to correct or prevent regulatory violations.

7. Recommend such actions or measures to be adopted by the Board that the Committee deems appropriate to improve the effectiveness of the Company's Global Compliance and Ethics Program and the Company's Global Quality and Regulatory Program.

(c) In the performance of its duties, the Committee is expected to perform the following specific activities:

1. Perform, or have performed, an evaluation of the performance of the CECO and the Company's compliance function and personnel.

2. Review and approve an annual Global Compliance and Ethics Program plan developed by the CECO.

3. Review an annual Compliance and Ethics Program report provided to the Committee by the CECO, summarizing compliance-related activities undertaken by the Company and the results of all compliance audits.

4. Meet with, and receive reports from, the CECO regarding the CECO's performance and activities, the performance and activities of the Company's compliance function and personnel, and the operations of the Company's Global Compliance and Ethics Program generally.

5. Review new and ongoing investigations into compliance hotline reports and compliance investigations maintained in the Company's third-party case management system.

6. Review and consider, as relevant, legal, compliance, and/or industry changes that may affect the Company's business, Global Compliance and Ethics Program and Global Quality and Regulatory Program.

(d) The Committee has the authority to perform such other duties and responsibilities as may be assigned to the Committee by the Board.

(e) It is the intention of the Board and the Committee that all communications with the CECO and Chief Legal Officer, and any inside or outside legal counsel (including without limitation those described above) shall be deemed to constitute communications for the purpose of obtaining legal advice and are therefore privileged attorney-client communications.

5. Governance Requirements

The chairperson of the Committee or a majority of the Committee members may call meetings of the Committee at any time and for any reason. The notice of meeting need not include specified agenda items and must be provided to the Committee members no less than 24 hours prior to any meeting using any method available under the Governance Requirements. Attendance at any meeting of the Committee shall constitute a waiver of the notice requirement by such member. Meetings may be held using any form of communications equipment, so long as all Committee members participating in the meeting can communicate with each other in real-time, including, but not limited to, via conference call, e-mail, instant messaging or otherwise using a virtual platform. A majority of the Committee members will constitute a quorum for the transaction of Committee business, and the vote of a majority of the Committee members present at a meeting at which a quorum is present will be the act of the Committee, unless in either case a greater number is required by the Governance Requirements. Additionally, the Committee may act by unanimous written consent of all Committee members, or by unanimous consent evidenced by any other form of communication, whether or not directly involving the physical transmission of paper, that creates a record that may be retained, retrieved, and reviewed by a recipient thereof, and that may be directly reproduced in paper form by such a recipient through an automated process, unless such action in such matter is expressly prohibited by the Governance Requirements.

Last revised on December 14, 2023.